Edesa Biotech Inc (NASDAQ:EDSA) — Market Cap & Net Worth
Market Cap & Net Worth: Edesa Biotech Inc (EDSA)
Edesa Biotech Inc (NASDAQ:EDSA) has a market capitalization of $49.23 Million ($49.23 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21874 globally and #4811 in its home market, demonstrating a -9.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Edesa Biotech Inc's stock price $5.11 by its total outstanding shares 9633223 (9.63 Million). Review EDSA FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
Edesa Biotech Inc Market Cap History: 2015 to 2026
Edesa Biotech Inc's market capitalization history from 2015 to 2026. Data shows change from $18.38 Billion to $49.23 Million (-42.83% CAGR).
Index Memberships
Edesa Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #622 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2092 of 3165 |
Weight: Edesa Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Edesa Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Edesa Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
759290.64x
Edesa Biotech Inc's market cap is 759290.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.75 Billion | $1.27 Million | -$5.03 Million | 4521.00x | N/A |
| 2017 | $2.29 Billion | $228.29K | -$5.03 Million | 10049.00x | N/A |
| 2018 | $368.18 Million | $211.85K | -$5.04 Million | 1737.94x | N/A |
| 2019 | $276.47 Million | $410.87K | -$2.72 Million | 672.90x | N/A |
| 2020 | $286.59 Million | $328.80K | -$6.36 Million | 871.62x | N/A |
| 2021 | $379.65 Million | $500.00 | -$13.34 Million | 759290.64x | N/A |
Competitor Companies of EDSA by Market Capitalization
Companies near Edesa Biotech Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Edesa Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Edesa Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Edesa Biotech Inc's market cap moved from $18.38 Billion to $ 49.23 Million, with a yearly change of -42.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.23 Million | +259.86% |
| 2025 | $13.68 Million | -15.48% |
| 2024 | $16.18 Million | -63.24% |
| 2023 | $44.02 Million | -69.78% |
| 2022 | $145.65 Million | -61.63% |
| 2021 | $379.65 Million | +32.47% |
| 2020 | $286.59 Million | +3.66% |
| 2019 | $276.47 Million | -24.91% |
| 2018 | $368.18 Million | -83.95% |
| 2017 | $2.29 Billion | -60.10% |
| 2016 | $5.75 Billion | -68.72% |
| 2015 | $18.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Edesa Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.23 Million USD |
| MoneyControl | $49.23 Million USD |
| MarketWatch | $49.23 Million USD |
| marketcap.company | $49.23 Million USD |
| Reuters | $49.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more